12:00 AM
 | 
Apr 10, 2000
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Sugen preclinical data

Oral administration of SU6668 to mice produced tumor regression of epidermoid and colon tumors and growth arrest of brain, lung...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >